Global Alzheimer's Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer's Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer's disease. Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer's—a critical element in accurately diagnosing Alzheimer's disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF).
GAP is proud that its AD biomarker study, Bio-Hermes-001, played a principal role in the dataset used to support Fujirebio's FDA application for clearance of the first groundbreaking blood based IVD available for the diagnosis of Alzheimer's Disease (AD). Bio-Hermes-001 was designed to provide head-to-head comparisons of data available on leading Alzheimer's blood tests and PET tests from 1,000 highly characterized and representative study volunteers demonstrating signs and symptoms associated with Alzheimer's disease.
John Dwyer, President of the Global Alzheimer's Platform Foundation stated, 'We commend the FDA's clearance of Fujirebio's Lumipulse submission, as this IVD is poised to fundamentally change the Alzheimer's diagnostic process and significantly improve the ability of physicians to accurately access and treat AD and empower people to take action to address their condition. GAP is extremely proud that its Bio-Hermes-001 biomarker study materially contributed to this landmark IVD. We intentionally designed that unique study to drive forward new technologies and treatment processes for Alzheimer's and related dementias. We want to thank the thousand volunteers who participated in Bio-Hermes 1; the numerous clinical trial sites that tirelessly worked with us on the study as well as the dozens of technology, pharmaceutical, and philanthropy partners that collaborated with us to support Bio-Hermes. GAP celebrates this remarkable clearance, which has the potential to transform the future of AD diagnostics and treatments.'
About the Global Alzheimer's Platform Foundation (GAP)The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.
Contact: media@globalalzplatform.org
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
‘Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, market analysis suggests. A 2025 report published by GlobalData, which analysed the seven major markets of the US, UK, France, Germany, Italy, Spain, and Japan, forecasts sector sales will reach the $22.4bn figure by 2033, up from $8.5bn in 2023, reflecting a compound annual growth rate (CAGR) of 10.2%. While not as fast-growing as the weight loss market in the metabolic disease space, the AD market growth is salient given the market's size compared to other dermatology indications. GlobalData healthcare analyst, Filippos Maniatis, comments: 'AD is a growing market with an impressive pipeline of new products from current and future players in the field. The AD space was previously dominated by broad-acting immunomodulatory agents, which are now being slowly replaced by more targeted agents. This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents.' GlobalData is the parent company of Pharmaceutical Technology. One of those targeted agents that has taken the market by storm is Regeneron and Sanofi's jointly developed Dupixent (dupilumab), first approved in the US in 2017. The blockbuster monoclonal antibody has seen its sales increase year-over-year amid high uptake from AD – reaching $14.9bn in sales in 2024. Dupixent is approved for a range of diseases, including a lucrative asthma indication. The report says that the gap of unmet need in AD, which is closing courtesy of Sanofi and Regeneron, is set to shrink even further depending on future approvals for more targeted therapies. One modality poised as a future disruptor is the OX40 inhibitor class of drugs that work by inhibiting T-cell activation and inflammation via the OX40 receptor on the immune cells. Pipeline candidates in development include Amgen and Kyowa Kirin's rocatinlimab, Sanofi's amlitelimab, and Astria Therapeutics' telazrolimab. Another class with a potential future in AD is interleukin (IL) inhibitors. LEO Pharma, GSK, and Nektar all have assets in clinical development. Maniatis concludes: 'With multiple pipeline agents in development, key unmet needs may be further addressed. Such unmet needs include the lack of personalised treatments through improved diagnostic methods, the high cost of current therapy options, the limited therapeutic options for chronic hand eczema, and better long-term disease control and management.' "'Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
The Hill
an hour ago
- The Hill
Blue states call on FDA to expand abortion pill access
Attorneys general of New York, California, New Jersey and Massachusetts are asking the Food and Drug Administration (FDA) to expand access to the abortion pill and remove some 'unnecessary' drug restrictions that have been in place for more than two decades. The joint petition, filed Thursday, comes days after FDA Commissioner Marty Makary committed to reviewing the abortion drug amid pressure from Department of Health and Human Services Secretary Robert F. Kennedy Jr. and some Republican lawmakers. The FDA first approved of the use of mifepristone and misoprostol for an abortion in 2000. Unlike surgical abortions, medication abortions do not need to take place in a clinical setting, and patients are able to take the pills at home. Most abortions in the U.S. are now medication abortions, according to data from the reproductive health and rights group Guttmacher Institute. In 2023, 63 percent of all abortions in the U.S. were medication abortions. The safety of mifepristone has come under increased scrutiny by some Republican lawmakers, citing a flawed study claiming the rate of adverse health events that occur among patients is far higher than previously reported. More than 100 scientific studies have been conducted looking at the safety and efficacy of mifepristone and misoprostol; all of them have found that the drugs are a safe way to terminate a pregnancy. 'Given Mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' Mifepristone's use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program under the FDA. The attorneys general argue three requirements under the REMS program for the drug should be removed since they pose a burden to patients and health care systems. The first is related to prescriber certification. As part of the REMS program, health care providers who prescribe mifepristone are required to add their names to national and abortion provider lists, which the attorneys general say raise 'serious safety and legal concerns.' The second has to do with patient agreement forms. All patients who want mifepristone — even those using the drug to treat a miscarriage — are required to sign a document stating they are using the drug to end a pregnancy. The third requirement mentioned in the petition is connected to pharmacy certification. As part of mifepristone's REMS program, pharmacies that carry the drug are subject to tracking, shipping and reporting requirements, which the attorneys general argue may 'dissuade' some from carrying the drug. The FDA has yet to reply to a request for comment from The Hill about the petition.
Newsweek
an hour ago
- Newsweek
Albertsons Food Recalled in 12 States as FDA Issues Most Severe Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Albertsons Companies has issued a voluntary recall of multiple store-prepared Greek salad products sold across 12 states and Washington, D.C. The U.S. Food and Drug Administration (FDA) has classified the alert as a Class I recall—its highest and most urgent warning level. The salads were made using cucumbers linked to a multistate salmonella outbreak traced back to Bedner Growers Company. Newsweek has contacted Albertsons, via email, and Bedner Growers Company, via online contact form, for comment. Why It Matters A Class I recall is reserved for products that pose a serious health risk with a "reasonable probability" of causing illness or even death if consumed. The recalled Greek salads were sold under several store brands in high-traffic northeastern grocery chains. The FDA warning elevates the urgency for consumers who may still have the product in their refrigerators, particularly those with compromised immune systems, children, and elderly individuals more vulnerable to foodborne illnesses. What to Know Recalled Products: AMCE Greek Salad AUTHENTIC FS Sold refrigerated in clear plastic containers by the pound UPC: 293070 ##### READY MEALS Greek Salad SS Sold refrigerated in clear plastic containers by the pound UPC: 292483 ##### Star Market Greek Salad FS Sold refrigerated in clear plastic containers by the pound UPC: 292329 ##### Reason for Recall: All three products contain cucumbers from Bedner Growers Company, which were previously recalled due to contamination with salmonella, a bacteria known to cause serious gastrointestinal illness. The outbreak has been under ongoing investigation by public health authorities. Where the Recall Applies: The salads were sold at stores in the following states: Connecticut Delaware Maine Massachusetts Maryland New Hampshire New Jersey New York Rhode Island Pennsylvania Vermont Virginia Washington, D.C. The affected salads were primarily sold in ACME, Star Market, and Ready Meals outlets. What People Are Saying Albertsons Companies stated in its press release that it is "committed to the highest standards of food safety" and that the recall was initiated "out of an abundance of caution." No illnesses have been officially linked to the salads yet, but the company has urged customers who purchased any of the listed products to discard them immediately or return them to the store for a full refund. The FDA emphasized the seriousness of the recall, pointing to the ongoing multistate salmonella outbreak and reiterating its warning that contaminated food—even if it looks or smells normal—can be dangerous. What's Next The full scope of the salmonella outbreak connected to the contaminated cucumbers is being investigated. Consumers are advised to check their refrigerators for any of the recalled Greek salad items and follow safety instructions. Albertsons said affected stores are posting notices and removing products from shelves. Additional recalls may be issued if more prepared foods containing the same contaminated cucumbers are identified.
